Patents by Inventor Dwight-Steven Hill
Dwight-Steven Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7989678Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.Type: GrantFiled: August 31, 2005Date of Patent: August 2, 2011Assignee: BASF Plant Science GmbHInventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey A. Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan Richard Wenck, Larry Nea
-
Publication number: 20070292953Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.Type: ApplicationFiled: August 31, 2005Publication date: December 20, 2007Applicant: BASF Plant Science GmbHInventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan Wenck, Larry Nea
-
Publication number: 20030135880Abstract: This invention describes methods, transgenic plants and transgenic microorganisms for the biosynthesis of halogenated natural products, where the halogenation is substrate and regiospecific. In particular, this invention relates to the use of halogenated metabolites, produced by the method of the invention, for the protection of host organisms against pathogens, more particularly, to the protection of plants against phytopathogens. In this aspect, the invention provides transgenic plants with enhanced resistance to phytopathogens, and biocontrol organisms with enhanced biocontrol properties.Type: ApplicationFiled: July 2, 2002Publication date: July 17, 2003Inventors: John Steffens, Chris Batie, Jon Marquiz Dietz, Jian Dong, Kim Puloma Kamdar, Dwight Steven Hill
-
Publication number: 20030068788Abstract: Disclosed is a family of P450 monooxygenases, each member of which regioselectively oxidizes avermectin to 4″-keto-avermectin. The P450 monooxgenases find use in methods and formulations for making emamectin from avermectin. Also disclosed are methods for purifying the P450 monooxygenases of the invention, binding agents that specifically bind to the P450 monooxygenases of the invention, and genetically engineered cells that express the P450 monooxygenases of the invention. Also disclosed are ferredoxins and ferredoxin reductases that are active with the P450 monooxygenases of the invention.Type: ApplicationFiled: May 14, 2002Publication date: April 10, 2003Inventors: Thomas Gunther Buckel, Philip Eugene Hammer, Dwight Steven Hill, James Madison Ligon, Istvan Molnar Durham, Johannes Paul Pachlatko, Ross Eric Zirkle
-
Patent number: 6117670Abstract: The present invention is directed to the production of pyrrolnitrin in a host via recombinant expression of the polypeptides needed to biologically synthesize pyrrolnitrin. Genes isolated from P. fluorescens, P. pyrrocinia, B. cepacia, and M. fulvus that encode polypeptides necessary to produce pyrrolnitrin are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize pyrrolnitrin from any organism capable of producing pyrrolnitrin. The isolated genes may be transformed and expressed in a desired host organisms to produce pyrrolnitrin according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of pyrrolnitrin.Type: GrantFiled: February 24, 1998Date of Patent: September 12, 2000Assignee: Novartis Finance CorporationInventors: James Madison Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip Eugene Hammer, Karl-Heinz van Pee, Sabine Kirner, Thomas R. Young
-
Patent number: 5955348Abstract: Strains of Pseudomonas have been genetically engineered to have enhanced biocontrol properties. The strains of the invention are particularly effective against plant pathogenic fungi such as species of Rhizoctonia and Pythium, because the strains produce enhanced amounts of antifungal metabolites such as pyrrolnitrin that are active against these fungal pathogens. Both the genetically modified biocontrol strains and the antifungal metabolites can be used as active agents for biocontrol compositions.Type: GrantFiled: November 25, 1997Date of Patent: September 21, 1999Assignee: Novartis AGInventors: James Madison Ligon, Nancy R. Torkewitz, Dwight Steven Hill, Thomas Deane Gaffney, Jill Michelle Stafford
-
Patent number: 5817502Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: October 9, 1996Date of Patent: October 6, 1998Assignee: Novartis Finance CorporationInventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer, Karl-Heinz van Pee, Sabine Kirner
-
Patent number: 5723759Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 1, 1995Date of Patent: March 3, 1998Assignee: Novartis Finance CorporationInventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
-
Patent number: 5710031Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.Type: GrantFiled: June 2, 1995Date of Patent: January 20, 1998Assignee: Novartis Finance CorporationInventors: Thomas D. Gaffney, Stephen T. Lam, James M. Ligon, Dwight Steven Hill, Jeffrey I. Stein
-
Patent number: 5698425Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 1, 1995Date of Patent: December 16, 1997Assignee: Novartis Finance CorporationInventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
-
Patent number: 5679560Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 1, 1995Date of Patent: October 21, 1997Assignee: Novartis Finance CorporationInventors: James M. Ligon, Dwight Steven Hill, Stephen Ting Lam, Philip E. Hammer
-
Patent number: 5670350Abstract: Gene activating sequences which activate the expression of other bacterial genes, which are latent or expressed at low levels, are provided. The gene activating sequences confer the ability to produce several metabolites and may be transferred to bacterial strains. The transformed biocontrol agents are active to inhibit the growth of the fungal pathogens.Type: GrantFiled: August 8, 1994Date of Patent: September 23, 1997Assignee: Novartis Finance CorporationInventors: Thomas D. Gaffney, Stephen T. Lam, Dwight Steven Hill, Jeffrey I. Stein, James M. Ligon
-
Patent number: 5662898Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 1, 1995Date of Patent: September 2, 1997Assignee: Ciba-Geigy CorporationInventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
-
Patent number: 5643774Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 1, 1995Date of Patent: July 1, 1997Assignee: Ciba-Geigy CorporationInventors: James M. Ligon, Thomas Schupp, James Joseph Beck, Dwight Steven Hill, John Andrew Ryals, Thomas Deane Gaffney, Stephen Ting Lam, Philip E. Hammer, Scott Joseph Uknes
-
Patent number: 5639949Abstract: The present invention is directed to the production of an antipathogenic substance (APS) in a host via recombinant expression of the polypeptides needed to biologically synthesize the APS. Genes encoding polypeptides necessary to produce particular antipathogenic substances are provided, along with methods for identifying and isolating genes needed to recombinantly biosynthesize any desired APS. The cloned genes may be transformed and expressed in a desired host organisms to produce the APS according to the invention for a variety of purposes, including protecting the host from a pathogen, developing the host as a biocontrol agent, and producing large, uniform amounts of the APS.Type: GrantFiled: June 8, 1994Date of Patent: June 17, 1997Assignee: Ciba-Geigy CorporationInventors: James M. Ligon, Dwight Steven Hill, John Andrew Ryals, Stephen Ting Lam, Philip E. Hammer
-
Patent number: RE44750Abstract: The present invention relates “disarmed” strain variants of Agrobacterium strain K599 (NCPPB 2659), “disarmed” plasmid variants of the Ri-plasmid pRi2659, and derivatives thereof, and methods employing these strains and plasmids in plant transformation.Type: GrantFiled: September 10, 2012Date of Patent: February 4, 2014Assignee: BASF Plant Science GmbHInventors: Luke Mankin, Dwight-Steven Hill, Paula Olhoft, Effie Toren, Jeffrey A. Brown, Liqun Xing, Huihua Fu, Lesley Ireland, Hongmei Jia, Hee-Sook Song, Allan R. Wenck, Larry Nea